Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.kilitch.com | |
Market Cap | 540.77 Cr. | |
Enterprise Value(EV) | 560.13 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 8.73 | Trailing Twelve Months Ending 2023-09 |
Price-Earning Ratio (PE) | 38.54 | Trailing Twelve Months Ending 2023-09 |
Industry PE | 38.75 | Trailing Twelve Months Ending 2023-09 |
Book Value / Share | 104.10 | Trailing Twelve Months Ending 2023-09 |
Price to Book Value | 3.23 | Calculated using Price: 336.25 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 1.61 Cr. | 16,082,319 Shares |
FaceValue | 10 | |
About Kilitch Drugs (India) Ltd. | ||
Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms. With nearly two decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a healthier place. |
1 Day |
|
+1.99% |
1 Week |
|
+4.75% |
1 Month |
|
+29.83% |
3 Month |
|
+81.76% |
6 Month |
|
+58.76% |
1 Year |
|
+115.82% |
2 Year |
|
+113.49% |
5 Year |
|
+91.00% |
10 Year |
|
+1619.95% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | -0.25 | -9.91 | -8.59 | 4.95 | 3.36 | 0.71 | 3.09 | 4.73 | 5.86 | |
Return on Capital Employed (%) | -0.74 | -10.11 | -8.69 | 6.08 | 7.59 | 1.95 | 4.40 | 7.26 | 10.26 | |
Return on Assets (%) | -0.19 | -9.25 | -7.86 | 4.36 | 2.85 | 0.59 | 2.19 | 3.03 | 3.89 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 120 | 109 | 101 | 112 | 121 | 118 | 127 | 139 | 152 | 167 | |
Non Curr. Liab. | -1 | -1 | -2 | -2 | -1 | -1 | -1 | -1 | -2 | -3 | |
Curr. Liab. | 7 | 8 | 12 | 15 | 20 | 22 | 73 | 69 | 69 | 70 | |
Minority Int. | 1 | 2 | 2 | 2 | 1 | -1 | -1 | ||||
Equity & Liab. | 126 | 116 | 110 | 126 | 143 | 142 | 202 | 208 | 218 | 234 | |
Non Curr. Assets | 79 | 68 | 62 | 63 | 78 | 86 | 122 | 94 | 91 | 91 | |
Curr. Assets | 47 | 47 | 49 | 63 | 65 | 56 | 80 | 114 | 126 | 144 | |
Misc. Exp. not W/O | 0 | 0 | |||||||||
Total Assets | 126 | 116 | 110 | 126 | 143 | 142 | 202 | 208 | 218 | 234 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09 Rs. Cr. TTM |
Net Sales | 19 | 21 | 29 | 51 | 82 | 53 | 69 | 114 | 140 | 153 | |
Other Income | 3 | 3 | 1 | 3 | 5 | 5 | 3 | 3 | 3 | 3 | |
Total Income | 22 | 24 | 30 | 54 | 88 | 58 | 71 | 117 | 143 | 156 | |
Total Expenditure | -21 | -25 | -29 | -46 | -76 | -53 | -63 | -104 | -122 | -128 | |
PBIDT | 1 | -2 | 1 | 9 | 11 | 5 | 8 | 13 | 21 | 28 | |
Interest | 0 | 0 | 0 | 0 | -1 | -1 | -1 | -1 | -5 | -6 | |
Depreciation | -2 | -10 | -10 | -2 | -2 | -2 | -2 | -2 | -4 | -3 | |
Taxation | 1 | 0 | 0 | -1 | -5 | -1 | -1 | -3 | -4 | -6 | |
Exceptional Items | |||||||||||
PAT | 0 | -11 | -9 | 5 | 4 | 1 | 4 | 6 | 8 | 13 | |
Minority Interest | 0 | 1 | 2 | 1 | |||||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 0 | -11 | -9 | 5 | 4 | 1 | 4 | 7 | 10 | 14 | |
Adjusted EPS | 0 | -8 | -7 | 4 | 2 | 1 | 2 | 5 | 7 | 9 |
Particulars | 10 years | 2012-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | -29 | -8 | 17 | 1 | 1 | 0 | 4 | 46 | 6 | 3 | |
Cash Fr. Inv. | 41 | -31 | -20 | -2 | -4 | -14 | -10 | -38 | -15 | 8 | |
Cash Fr. Finan. | -9 | 0 | 0 | 0 | 6 | 17 | 1 | 2 | 7 | -1 | |
Net Change | 2 | -39 | -2 | 0 | 2 | 3 | -5 | 10 | -2 | 10 | |
Cash & Cash Eqvt | 12 | 5 | 3 | 2 | 5 | 8 | 3 | 13 | 10 | 20 |
Wed, 22 Nov 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of Loss of Share Certificate received from shareholder of the Company. |
Sat, 11 Nov 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Please find enclosed copy of new paper publication pertaining to extract of the financial results of the Company for the quarter ended 30th September 2023 |
Thu, 09 Nov 2023
Financial Results For The Quarter Ended 30Th September 2023 Enclosed please find Financial Results for the quarter ended 30th September 2023 |
Fri, 01 Dec 2023 |
|
|
|
|
|